We are LikeMinds, a radiopharmaceutical company that aims to provide a precise, early, accurate and ultimately actionable diagnosis of Parkinson’s, dementia and other dopamine-related brain diseases.
This is a big challenge with equally big implications. Degenerative brain diseases progress undetected for up to 20 years before detectable symptoms appear. By then, a patient’s viable dopamine receptors have significantly declined, leading to diseases like Parkinson’s and Lewy Body dementia. As a result, early and accurate detection of the type of tremor is critical to taking advantage of potential therapies.
LikeMinds is taking on this challenge, by developing and commercializing an imaging agent platform capable of supporting early detection of those diseases and dysfunctions related to changes in dopamine receptor function.